Propofol is a safe, well-tolerated anesthetic that is labeled as contraindicated in patients with egg or soy allergy. This contraindication has become increasingly problematic given the rising incidence of food allergy and eosinophilic esophagitis (EoE). To address this issue, we studied practice patterns of propofol use for esophagogastroduodenoscopies in children with EoE and food allergies at our institution. A retrospective observational study of 1365 esophagogastroduodenoscopies from January 2013 to June 2014 was performed. Data were analyzed using Student t tests, chi square tests, Fisher exact tests, and multivariable logistic regression. We found that propofol was used significantly less in patients with egg or soy allergy, and in patients with EoE, even after adjusting for the presence of food allergy. There was no difference in complication rates relative to propofol use. Propofol was used safely in pediatric patients with EoE and food allergy in this limited single-center review.
P
ropofol (2,6-diisopropylphenol) is commonly used as an anesthetic agent during pediatric esophagogastroduodenoscopy (EGD) (1) . Because propofol contains egg phospholipids and soybean oil, it is contraindicated in patients with egg or soy allergy (2). Although egg phospholipids and soybean oils are not thought to be allergenic (3, 4) , there remains a theoretical risk of crosscontamination with egg or soy protein and case reports implicate propofol as the inciting trigger for immunoglobulin E (IgE)-mediated reactions in some patients with egg or soy allergy (5-7). In contrast, some studies and clinical practice suggest that propofol is safe to use in patients with these allergies (8, 9) . This issue has become even more relevant given an increasing incidence of eosinophilic esophagitis (EoE), a disease characterized by food allergies and the need for frequent endoscopies.
Because of this clinical conundrum, we studied the practice patterns with respect to propofol use in children with EoE and food allergies at our institution. We performed a retrospective analysis determining the rate of propofol use and associated complications in children undergoing EGD with a clinical history of egg or soy allergy or EoE.
METHODS
Screening of EPIC medical records of all children ages 0 through 18 years who underwent general anesthesia for EGD at Children's Hospital Colorado (CHCO) from January 1, 2013 to June 30, 2014 was used to identify patients. Patients were excluded from analyses if procedures other than pH impedance were simultaneously performed with the EGD. Comorbidities and allergies were determined by reviewing the patient's problem list and were included if listed before the EGD date. Personal and familial anesthetic histories were obtained from the anesthesiologist's preoperative notes. Complications were determined by reading all postoperative notes completed within 1 week of the procedures. The present study was approved by the Colorado Multiple Institutional Review Board with a waiver of informed consent.
Data were analyzed using a Student t test for continuous variables and Pearson x 2 test and Fisher exact test for categorical
What Is Known
Propofol is commonly used for pediatric anesthesia given its safety and favorable side effect profile. Because it is formulated with an egg and soy-based lipid solvent, propofol use is controversial in children with food allergy.
What Is New
Propofol is frequently used in egg or soy allergic patients despite a contraindication warning on the package insert.
Patients with eosinophilic esophagitis are less likely to receive propofol even after accounting for egg or soy allergy. Propofol was used safely for esophagogastroduodenoscopies in pediatric patients with eosinophilic esophagitis or food allergy in this single-center review.
variables. Multivariable logistic regression was used to determine the odds of using propofol after adjusting for age, sex, comorbidities, and presence of egg or soy allergy. Because 6% of patients had more than 1 EGD, additional sensitivity analysis was performed. A generalized estimation equation was used to account for the clustering effect of repeated EGDs on the same patient. Multivariable logistic regression was also performed after excluding data from repeated measures of multiple EGDs. Statistical analysis was carried out using SAS software package 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS

Characteristics of the Patient Population
Chart review of the medical records of 1365 EGDs performed on 1279 patients was completed (Table 1) . General anesthesia was used for all procedures and was performed by 48 anesthesiologists. Fifteen procedures were performed on 12 patients with a history of anaphylaxis to egg; propofol was used in 6 of these. One patient had 3 procedures-the first 2 without propofol and the third with propofol. One procedure was performed on a patient with a history of anaphylaxis to soy and propofol was not given. No significant differences were identified in American Society of Anesthesiologists classifications between patients who received propofol and those who did not (P ¼ 0.88).
Propofol Use in Food Allergic and Eosinophilic Esophagitis Patients
Propofol was used significantly more in patients without egg or soy allergy than those with allergy (72% vs 40%, P < 0.0001). Propofol was used significantly less in patients with EoE than those without EoE (55% vs 71%, P < 0.0001). Propofol was used significantly more in older children (11 vs 7 years, P < 0.001) and in girls (71% vs 65%, P ¼ 0.02). After adjusting for possible confounders including the presence of egg or soy allergy, sex, age, and asthma, patients without EoE were still significantly more likely to receive propofol than those with EoE (P ¼ 0.04). In the adjusted analysis, patients without EoE were 40% more likely to receive propofol than those with EoE (odds ratio 1.4, 95% confidence interval [1.02, 1.92]). The adjusted odds ratios are depicted in Figure 1 .
Complication Rates
Procedural complications are described in Table 2 . No hospital admissions or anaphylactic episodes were identified in any patient. There was no significant difference in total complication rates between patients who received propofol and those who did not regardless of allergic or EoE diagnoses. One respiratory FIGURE 1. Adjusted odds ratios for using propofol after controlling for presence of age, sex, egg/soy allergy, asthma, and EoE. The odds of using propofol for esophagogastroduodenoscopies performed on patients without egg or soy allergy are 2.5 times greater than those performed on patients with food allergy. Procedures performed on patients without EoE are 40% more likely to be performed with propofol even after adjusting for presence of egg or soy allergy. EoE ¼ eosinophilic esophagitis; OR ¼ odds ratio.
complication was recorded in a non-EoE, egg/soy allergic child who received propofol. This 3-year-old girl had a history of recent upper respiratory infection and developed postoperative laryngeal irritability. She required positive pressure ventilation and albuterol nebulization, was treated with cool mist oxygen, and discharged home on room air.
DISCUSSION
Pediatric patients with EoE frequently require sedated endoscopies for management of their disease. Propofol is an anesthetic agent commonly used during endoscopy; however, it is contraindicated in patients with egg or soy allergy. Because EoE is associated with food allergy, propofol use in this patient population is controversial. Therefore, we performed a retrospective review of EGDs in pediatric patients over a 1.5-year period in our tertiary care children's hospital. We found that patients with egg or soy allergy were less likely to receive propofol. Patients with EoE were also less likely to receive propofol even after adjusting for the presence or absence of egg or soy allergy. Finally, there was no difference in rate of anesthetic complications in patients who received propofol relative to those who did not, irrespective of their diagnosis of EoE or food allergy. In this series, propofol was safely administered to pediatric patients with EoE and food allergy.
Our study showed that nearly half of all EGDs on soy or egg allergic patients were performed with propofol. Thus, despite its contraindication, propofol is commonly used for pediatric patients with egg or soy allergy at our institution. This practice is consistent with other studies documenting that propofol is commonly used in these patients despite the warning. Based on the fact that no significant adverse events were found in 149 procedures performed on 131 children with soy, egg, or nut allergies, Wiskin et al (10) reported that propofol is the sole anesthetic agent used for pediatric EGDs in their institution. They were careful to report that this group included those with IgE and non-IgE-mediated allergies.
In our study, even after adjusting for egg or soy allergy, propofol was used less frequently in patients with EoE. The reasons for this are unclear; however, we hypothesize that it may be due to concerns about the potential for unidentified soy or egg allergy in a patient population with a disease process that is often food allergen driven. Despite the prevalence of egg and soy allergy among patients with EoE, only 1 study has examined propofol use in this population. Molina-Infante et al performed a retrospective chart review of 60 adult patients with EoE sensitized to egg, soy, or peanut who received propofol. Similar to our findings, they did not identify anaphylactic reactions or severe adverse reactions in patients with EoE with egg and soy allergy and concluded that propofol could safely be administered to egg or soy allergic patients (11) .
Some studies suggest that patients may have physical responses to propofol that are not IgE mediated. For instance, patients may have allergic responses that are due to chemical properties of propofol rather than crosscontamination with egg or soy. Laxenaire et al described a series of 14 patients who developed anaphylaxis to propofol and who later had confirmatory testing supporting hypersensitivity to propofol's phenyl or isopropyl group rather than egg. Several of these patients later had skin prick or intradermal testing to intralipid (a product that also contains egg lecithin and soybean oil) and were all found to be skin test negative (12) . In a larger adult study, Asserhoj et al (13) systematically investigated propofol allergy in patients with suspected perioperative allergic reactions by using serum tryptase, specific IgE levels, skin-prick testing, intradermal testing, and IV propofol provocation tests. The authors found that 2.6% of these patients had positive allergy tests and none had allergic symptoms when eating egg or soy. Finally, some patients may have non-IgE-mediated reactions to egg or soy that are yet to be well defined.
As the incidence of both pediatric food allergy and EoE continues to rise, the number of endoscopies performed on these patient populations will likely grow as well. Given propofol's warning, questions regarding the safety of propofol administration in this highly atopic group will likely persist. Propofol has been commonly used as an anesthetic for decades; however, the contraindication for its use in patients with egg or soy allergy began in 2007 (2,14) . The anesthetic properties of propofol were first described in 1973 with subsequent European clinical trials in the mid-1970s (15, 16) . The original formulation contained Cremophor EL, a castor oil-related substance, but was withdrawn due to a high rate of anaphylaxis (16) (17) (18) (19) . It was then reformulated using its current lipid-based emulsion in the mid-1980s and entered the US market in 1989 (16) . Despite the new formulation, several reports of anaphylaxis persisted through the next decade (5, 6, (20) (21) (22) . In 2007, the FDA issued an alert and revised the label to include a propofol infusion syndrome warning (2,23) and egg and soy allergy contraindication to use.
Studies seeking to fully assess the safety of propofol in egg and soy allergic children are not feasible to complete given the rarity of propofol allergy and the large numbers of patients needed to definitively answer this question. Because the incidence of allergic reaction to propofol is 1:10,000 to 1:20,000 and the incidence of propofol anaphylaxis is 1:60,000, a much larger sample size is needed to address the safety profile of propofol in the allergic population (24, 25) . We felt it was important to perform this retrospective study in spite of this issue because of our interest in EoE, the number of EGDs that these patients undergo, and the common presence of both IgE-and non-IgE-mediated food allergies. Our study has several limitations. Although propofol is an increasingly common choice for anesthesia, many factors other than EoE or allergies can influence its use. The diagnosis of food allergy was based on review of the medical record. Thus, whether these patients had IgE-or non-IgE-mediated food allergy is uncertain and could not be further characterized. Because physicians make medical decisions based on both parental report and medical records, the present study is reflective of real-life practices. Patients undergoing endoscopy may or may not have allergy testing results in their medical records. In addition, positive allergy tests may be indicative of sensitization rather than true allergy. Although the present study provides support that propofol is safe in patients with reported egg and soy allergy, the study cannot make a definitive statement regarding overall safety.
Results from our retrospective study of a limited number of patients found that propofol was used safely in children with EoE and in those with egg/soy allergy. Even after accounting for food allergy, it was used less frequently in patients with EoE. Further work is needed to better define food allergic diseases, understand potential mechanisms of propofol-related reactions, and determine optimal care of EoE patients who have IgE-and/or non-IgEmediated egg and soy allergies.
